SCHEMBL6516503

SCHEMBL6516503

Cc1ccc(S(=O)(=O)c2c[nH]c3ccc(Oc4c(Br)cc(CC(=O)O)cc4Br)cc23)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.58
SMN1; SMN2 Q16637 4/20 0.50
KDM4E B2RXH2 3/20 0.50
THRB P10828 9/20 0.46
THRA P10827 8/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
POLB P06746 2/20 0.42
DUSP3 P51452 1/20 0.42
PTPN5 P54829 1/20 0.42
PTPN11 Q06124 1/20 0.42
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
HTT P42858 3/20 0.41
LMNA P02545 2/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6512804 0.93 MAPT (0.55) MAPTSMN1; SMN2KDM4ETHRBTHRA
SCHEMBL6512816 0.91 THRB (0.50) MAPTTHRBTHRA
SCHEMBL6514008 0.91 SMN1; SMN2 (0.49) MAPTSMN1; SMN2KDM4ETHRBTHRA
SCHEMBL6522316 0.91 SMN1; SMN2 (0.49) MAPTSMN1; SMN2KDM4ETHRBTHRA
SCHEMBL6511181 0.90 MAPT (0.60) MAPTSMN1; SMN2KDM4ETHRBTHRA
SCHEMBL6524665 0.90 MAPT (0.60) MAPTSMN1; SMN2KDM4ETHRBTHRA
SCHEMBL6522045 0.89 MAPT (0.46) MAPTSMN1; SMN2KDM4ETHRBTHRA
SCHEMBL6520450 0.89 MAPT (0.58) MAPTSMN1; SMN2KDM4ETHRBTHRA
SCHEMBL6513862 0.89 THRB (0.44) MAPTTHRBTHRA
SCHEMBL6515118 0.88 SMN1; SMN2 (0.48) MAPTSMN1; SMN2KDM4ETHRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032874-A1 Anticholesterol agents; arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 2005-02-10 US disclosed
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
EP-1347959-A1 INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS Bayer Aktiengesellschaft (DE) 2003-10-01 EP disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed
WO-2002051805-A1 INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS BAYER AKTIENGESELLSCHAFT (DE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 MAPT 839/4885SMN1; SMN2 4749/4885KDM4E 1199/4885
US-20050032874-A1 Anticholesterol agents; arteriosclerosis HMGCR, CYP46A1, EBP MAPT 3453/4885SMN1; SMN2 4875/4885KDM4E 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.